REG - OptiBiotix Health - Director/PDMR Shareholding

OptiBiotix HealthAnnouncement

29/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260529:nRSc1387Ga&default-theme=true

RNS Number : 1387G  OptiBiotix Health PLC  29 May 2026

 

 

OptiBiotix Health plc

 

("OptiBiotix" or the "Company" or the "Group")

 

Director/PDMR Shareholding

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut microbiome,
and sweet fibres as healthy sugar substitute, announces that the Company has
been informed that David Blain, a Director of the Company, made the following
purchase of ordinary shares in the capital of the Company.

 

Further details are set out in the Notification of Dealing Form below.

 

 Director     Purchase price  Ordinary shares purchased  Resultant interest in ordinary shares  Resultant percentage of issued ordinary shares
 David Blain  6.17 pence      158,965                    243,018                                0.24%

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)                     Tel: 020 7213 0880
 Liam Murray / Ludovico Lazzaretti / James Western

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has
developed a range of technologies and commercialised products which modulate
the human microbiome to help prevent and manage human disease.  Since the
Group's inception it has created a wide range of microbiome-based ingredients
and products including prebiotic products like SlimBiome®, WellBiome®,
SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc
(OPTI) business, but also skincare through its holdings in SkinBioTherapeutics
PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies
create a diverse portfolio technologies and products in an emerging area of
healthcare that is of growing interest in consumer markets throughout the
world.

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         David Blain
 2   Reason for notification
 a.  Position/Status                                              Finance Director
 b.  Initial notification/                                        Initial Notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         OptiBiotix Health Plc
 b.  LEI                                                          213800UKYQFT941QHS14
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 2p each

Identification Code

                                                                  ISIN: GB00BP0RTP38
 b.  Nature of the transaction                                    Purchase of ordinary shares

 c.  Price(s) and volume(s)
                                                                               Price(s) per share  Volume(s)
     6.17 pence                                                                158,965

 d.  Aggregated information

     -       Volume                                               See above

     -       Price
 e.  Date of the transaction                                      28 May 2026
 f.  Place of the transaction                                     London Alternative Market (AIMX)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSELEFAEMSEDI



            Copyright 2019 Regulatory News Service, all rights reserved